Evidence map›Paper›PMID 32706528›Full record

ArticleCancer medicine2020

Regimen-intensity per count-recovery and hospitalization index: A new tool to assign regimen intensity for AML.

Mohamed L Sorror, Shirali Agarwal, Megan Othus, Ylinne Lynch, Jennifer E Nyland, Mary-Elizabeth Percival, Pamela S Becker, Frederick R Appelbaum, Elihu H Estey

Open access · goldAbstract readComparative Study
In one paragraph

Article in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Trial
  2. Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Mohamed L SorrorDivisions of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID 0000-0001-5260-1981
Shirali AgarwalDivisions of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Megan OthusDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID 0000-0001-8176-6371
Ylinne LynchDivisions of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Jennifer E NylandDivisions of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID 0000-0002-4549-3617
Mary-Elizabeth PercivalDivisions of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID 0000-0002-7016-951X
Pamela S BeckerDivisions of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Frederick R AppelbaumDivisions of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Elihu H EsteyDivisions of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa · ZAUniversity of Washington · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLow-intensity regimens have been increasingly used to treat older patients with acute myeloid leukemia (AML). Recent studies, however, suggest older patients can tolerate and potentially benefit from intensive chemotherapeutic regimens. The ability to compare the utility of varying regimen intensities in AML is hindered by the lack of a standardized definition of "regimen intensity."

methodsWe conducted a survey asking AML physicians which of 38 regimens they would consider intensive vs less-intensive. Electronic medical records of 592 patients receiving many of these regimens were used to design a model characterizing regimens as intensive vs less-intensive as identified by ≥75% physician consensus. Variables included frequency and length of hospitalizations, intensive care unit admissions, severe gastrointestinal toxicities, time to nadir, and recovery of neutrophil/platelet count.

resultsPhysicians agreed at a rate of 75%-100% on the assignment of degree of intensity to the majority (n = 28) of these regimens, while the level of agreement was <75% for the remaining 10 regimens (26%). Logistic regression analyses identified number and length of hospitalizations to be significantly associated with intensive regimens and count recovery with less-intensive regimens. We created the "regimen-intensity per count-recovery and hospitalization" (RICH) index with an AUC of 0.87. Independent model validation yielded an AUC of 0.75.

conclusionsWe were able to generate a novel model that defines regimen intensity for many therapies used to treat AML. Results facilitate a future randomized study comparing intensive vs less-intensive regimens.

Indexed as

Clinical Decision RulesHospitalizationAntineoplastic Combined Chemotherapy ProtocolsBlood PlateletsHealth Care SurveysHumansLeukemia, Myeloid, AcuteLeukocyte CountNeutrophilsPlatelet CountPredictive Value of TestsRisk AssessmentRisk FactorsTime FactorsTreatment Outcomeacute myeloid leukemiaexpert opinioninduction therapyintensitysurvey

Identifiers

PMID32706528
PMCPMC7520345
OpenAlexW3045050075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.